Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scientists from Biogen Idec have discovered that a receptor in the central nervous system may have a specific function in the neurons that degenerate during the progression of Parkinson's disease.
Subscribe to our email newsletter
This research is the first to suggest that inhibiting the Nogo-66 receptor (NgR1) may provide therapeutic benefit in the treatment of Parkinson’s disease.
Parkinson’s disease is a chronic disease of the central nervous system in which dopamine containing neurons in a part of the brain called the substantia nigra degenerate and die. The neurotransmitter dopamine, utilized by these neurons allows smooth, coordinated movement of the body. Current therapies can ease the symptoms of Parkinson’s disease, but none are able to slow or reverse its progression.
The new research by Biogen Idec scientists on an experimental model of Parkinson’s disease suggests that inhibiting the NgR1 pathway promotes dopaminergic cell survival in the substantia nigra region of the brain, increases dopamine levels in the affected areas, and improves behavioral response.
NgR1 is a receptor for three proteins found in myelin, the insulating substance that ensheathes axons. These proteins may inhibit nerve growth and may prevent nerve regeneration after injury. NgR1 may also accelerate nerve degeneration following injury. Biogen Idec scientists hypothesized that blocking NgR1 may slow degeneration of axons and prevent death of dopamine containing neurons in experimental Parkinson’s disease.